Neurocrine Biosciences Inc. NBIX
$158.44
▼ -1.81% 24H
About
Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for neurological, neuropsychiatric, endocrine, and metabolic disorders. Its flagship product, INGREZZA (valbenazine), a VMAT2 inhibitor, addresses tardive dyski…
SectorHealthcare
ExchangeNASDAQ
IndustryDrug Manufacturers - Specialty & Generic
CountryUnited States
Employees2,000
TickerNBIX
Statistics
Market Cap$15.94B
Revenue (TTM)$2.86B
Net Income$478.6M
Net Margin16.7%
EPS$4.67
P/E24.79
P/S5.21
P/B4.75
EV/EBITDA18.49
ROE22.5%
Dividend Yield—
Price$158.44
Data: Twelve Data · Revenue = mcap / P/S